The safety and performance of angioplasty using a normal-sized Gateway™ balloon and Wingspan™ stent for intracranial atherosclerotic stenosis were assessed. Seventy-two patients with intracranial stenosis (≥ 50%) were treated using an undersized (group U) or normal-sized (group N) Gateway™ balloon and a Wingspan™ stent. All patients were successfully stented. Stenosis improved from 74.2% before treatment to 23.8% immediately after treatment in group U and from 70.9% to 20.1% in group N. The two groups had similar rates of major periprocedural neurological complications (9.0% overall), none of which led to death. Residual stenosis at follow-up was 40.8% and 32.5% in groups U and N, respectively. In-stent re-stenosis (ISR) was significantly less frequent in group N (22.0%) than in group U (33.3%). It is concluded that use of a normal-sized Gateway™ balloon and Wingspan™ stent appears to be safe, to have a high rate of technical success, good immediate post-operative results and a low ISR rate.
Introduction
Ischaemic cerebrovascular disease, resulting mainly from intracranial atherosclerotic stenosis, has become a primary cause of death. The incidence of ischaemic stroke is approximately 33.3% 1 in Chinese patients with symptomatic intracranial atherosclerotic stenosis and ranges from 8% to 22% in Western countries. 2 Despite maximum medical therapy, such as aspirin and warfarin, about 10% of patients with symptomatic intracranial atherosclerotic stenosis will develop ischaemic stroke, 2,3 but as high as 60.7% has been reported, especially in patients with severe stenosis. 4 In recent years endovascular techniques have developed rapidly and endovascular intervention is becoming a commonly accepted form of treatment in patients with intracranial atherosclerotic stenosis. The Wingspan™ stent system (Boston Scientific, Natick, MA, USA) is the first self-*These authors contributed equally to this article. J Yu, L Wang, JP Deng et al. Normal-sized Gateway™ balloon for intracranial angioplasty expandable stent system designed for the treatment of intracranial atherosclerotic stenosis. It was approved in China in April 2007. The self-expanding nature of the Wingspan™ stent provides several unique advantages in comparison with the balloon type of expandable stent. For example, when deployed, the Wingspan™ stent exerts a continuous outward radial force on the vessel wall which prevents early vessel recoil, thus consolidating the gains achieved with the initial angioplasty. 5 Although periprocedural complications and mortality associated with the Wingspan™ system have been found to be acceptable in multicentre studies, 6, 7 relatively high rates of in-stent restenosis (ISR rate of 29.7%), defined as > 50% stenosis within or immediately adjacent (within 5 mm) to the implanted stent and > 20% absolute luminal loss, and complete stent thrombosis (rate of 4.8%), have been observed in follow-up. 8 The Gateway™ balloon is used to predilate the target lesion before Wingspan™ stenting. The operating manual, based on clinical studies, 5, 6, 9 advises that the balloon diameter should be sized to 80% of the normal parent vessel diameter and, if this is done, the system is relatively safe, but may still result in a high ISR rate. It was decided, however, to study the use of a normal-sized Gateway™ balloon and a Wingspan™ stent in the treatment of symptomatic intracranial atherosclerotic stenosis. A related analysis to investigate the safety of this form of the procedure was also performed.
Patients and methods

DATA COLLECTION
Between 26 April 2007 and 14 September 2009, patients with symptomatic intracranial stenoses undergoing attempted treatment with the Wingspan™ stenting system were enrolled at Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Oral informed consent was obtained from each patient before the experiment and the study was approved by the Ethics Committee of the Fourth Military Medical University, Xi'an, China. Enrolment required confirmation of 50 -99% stenosis by catheter angiography. 10 The patients were randomly divided into a group in which an undersized Gateway™ balloon was used (group U) or into a group in which a normalsized Gateway™ balloon was used (group N). The following were recorded: patient characteristics, stenosis details, procedural details, peri-procedural complications, data on vascular ultrasonography, transcranial Doppler, computed tomographic angiography and magnetic resonance angiography and angiographic follow-up results.
The percentage extent of stenosis of the target lesion was determined from the formula used in the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) study. 10, 11 The primary end-points were periprocedural stroke or death, stent success or procedural success. Stent success was defined as a reduction in the degree of stenosis to < 50% immediately after implantation, with adequate device performance. Procedural success was defined as stent success without stroke or death at discharge. Peri-procedural complications included parent vessel dissection, occlusion, rupture or perforation, vasospasm, symptomatic re-stenosis, stent migration and stenosis related or unrelated to cerebral infarction.
PROCEDURE
Percutaneous transluminal angioplasty and stenting was performed using the Wingspan™ system as described below. In all cases access was achieved through the common femoral artery. Each procedure was J Yu, L Wang, JP Deng et al.
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performed through a 6 F guiding catheter. Heparin was instituted to maintain an activated clotting time of two to three times the patient's baseline throughout the procedure.
The diameter of the stenotic lesion was measured by using biplane angiography and compared with the reference diameter of the normal vessel (usually proximal to the lesion) using the technique used in the WASID study. 10, 11 In all cases, after conventional catheterbased angiography, a Transend ® Floppy microwire (Boston Scientific, Natick, MA, USA) was manipulated across the target lesion. A Gateway™ angioplasty balloon was then manipulated across the target lesion over the microwire. The balloon length was selected to match the lesion length in all cases. The balloon diameter was sized to 80% of the normal diameter of the parent vessel in group U and to 90 -100% of the normal diameter in group N. Angioplasty was typically performed by graded inflation of the balloon to a pressure of between 6 and 12 atm for approximately 10 -20 s. After angioplasty, the balloon was removed and conventional angiography was repeated. Next, the Wingspan™ delivery system was advanced over the microwire across the target lesion. The stent diameter was sized to exceed the diameter of the normal parent vessel by 0.5 -1.0 mm. The stent length was sized to equal or exceed the length of the target lesion, so as to cover the diseased segment completely.
MEDICAL THERAPY
All patients were treated with the antiplatelet agents aspirin (300 mg/day) and clopidogrel (75 mg/day) for at least 3 days before surgery. This dual antiplatelet regimen was usually maintained for 3 months after the procedure. Clopidogrel was then discontinued if no stroke or transient ischaemic attack developed after follow-up. Aspirin (300 mg/day) therapy was usually continued for 6 months. All patients were scheduled to receive aspirin therapy (100 mg/day) for the rest of their lives if no stroke or transient ischaemic attack developed after follow-up.
The patients were pre-treated for common risk factors, including hypertension, hyperlipidaemia and diabetes, in order to maintain them in a relatively stable state. 12, 13 
STATISTICAL ANALYSIS
All data were processed with SPSS ® version 10.0 statistical software (SPSS Inc., Chicago, IL, USA). Single-factor analysis of variance was used to compare groups. Table 1 summarizes stenosis locations, baseline characteristics, post-procedural angiographic results, peri-procedural neurological complications and follow-up results for the two groups.
Results
A total of 77 stenoses in 72 patients (34 patients in group U [36 stenoses] and 38 in group N [41 stenoses]) were treated during the 29 months of the study, involving 25 females and 47 males of overall mean age 50.20 years. Baseline characteristics were similar between the two groups. All patients had symptomatic stroke with severe intracranial angiostenosis confirmed by angiography (≥ 50% stenosis). There was a history of stroke in 25 patients in group U and nine patients in group U had a history of transient ischaemic attack; the corresponding numbers of patients in group N were 26 and 12, respectively.
All patients were successfully stented and mean post-procedural residual stenosis was < 25% (range 1 -45%). Angiographs There were no significant differences 
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between the two groups in pre-procedural or post-procedural stenosis, frequency of periprocedural neurological complications or frequency of residual stenosis at follow-up. The incidence of ISR, however, was significantly (P < 0.05) higher in group U (33.3%) than in group N (22.0%). Five of the total of 21 (23.8%) patients in the two groups with ISR were symptomatic and required target vessel revascularization; they recovered well during the follow-up period.
The peri-procedural neurological complications included three stenosis-related infarctions (two cases in group N and one in group U) and one unrelated cerebral infarction (also in group N). There was also one case of parent vessel dissection (group N), one perforation (group U) and one stent migration (group U). The case of stent migration was treated by embedding another Wingspan™ stent to cover the entire stenosis. There was no parent vessel occlusion or rupture, vasospasm or symptomatic re-stenosis in either group and all other patients recovered well after symptomatic treatment. No deaths occurred in the peri-operative phase.
Discussion
The risk of ischaemic stroke in Chinese people with symptomatic intracranial atherosclerotic stenosis is higher than that in Western patients, 1,2 however, most previous trials with the Wingspan™ stent system have been in Western patients; trials in Asian, especially Chinese, people are rare. The present trial was a single-centre study of the Gateway™-Wingspan™ system involving patients in the north-west region of China. 1, 2 The baseline clinical characteristics of the whole patient population were similar to those of patients with intracranial atherosclerotic stenosis in previous clinical trials 5, 6 and were similar between the two groups. All patients required careful and intensive management of adjunctive risk factors, such as hypertension, hyperlipidaemia and diabetes.
Pre-procedural and post-procedural angiographic results and the frequency of peri-procedural neurological complications in group U were similar to those in group N. The frequency of ISR was significantly higher in group U than in group N and ISR is a wellknown disadvantage of the Wingspan™ system. 8 The frequency of ISR in group N was 22.0%, which is lower than that seen previously. 9 Most patients with ISR are asymptomatic, 8 however, once symptomatic ISR occurs, target vessel revascularization should be carried out. Target lesion revascularization can be performed for the treatment of symptomatic ISR with a relatively high degree of safety. 14 In the present study, five patients (23.8%) had symptomatic ISR and required target vessel revascularization; these patients showed good recovery at follow-up. The preprocedural angiographic results in group N were similar to those in a previous trial for intracranial stenosis treatment with the Wingspan™ stent system or NeuroLink ® (Guidant, Menlo Park, CA, USA) stent system. 5, 6 The post-procedural angiographic results in group N were better than those in the previous trial with the Wingspan™ stent system and similar to those with the NeuroLink ® stent system. 5, 6 The follow-up angiographic results in group N were also better than those obtained in these previous trials. 5, 6 Although the Wingspan™ stent system is the only self-expandable stent system approved by the US Food and Drug Administration for intracranial percutaneous transluminal angioplasty and stenting, it is possible that other types of stent may be more suitable for these lesions. The Stenting of 15 provided encouraging data on the safety and potential efficacy of the NeuroLink ® stent. Like other balloonexpandable stents, however, this stent has some disadvantages, such as difficult access to the target lesion and a high rate of periprocedural complications. 15, 16 To avoid these disadvantages of balloon-expandable stents and to exploit the advantages of the selfexpandable stent, a normal-sized Gateway™ balloon was employed with the Wingspan™ stent in the present study to treat intracranial atherosclerotic stenosis and the results confirm the safety and performance of this treatment.
Although the present study was performed at a single centre with a small sample of patients, the findings may be useful in assessing the potential effectiveness of angioplasty with the normal-sized Gateway™ balloon and Wingspan™ stent in the treatment of intracranial atherosclerotic stenosis. It could be argued that our treatment with the normal-sized Gateway™ balloon was too radical and could lead to unfavourable results with the Gateway™-Wingspan™ system. The data from group N, however, demonstrated that the treatment of intracranial atherosclerotic stenosis by angioplasty using a normal-sized Gateway™ balloon and a Wingspan™ stent produced an excellent result, without undue risks, in conditions similar to those used in group U. As we gain experience with more cases, more data will be accumulated and this should provide the basis for improved research in the future. Taking all the data together, we consider that adoption of a normal-sized Gateway™ balloon appears to make the Wingspan™ stent system more effective.
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